Jane Doe v. SEC

28 F.4th 1306
CourtCourt of Appeals for the D.C. Circuit
DecidedMarch 25, 2022
Docket21-1097
StatusPublished
Cited by16 cases

This text of 28 F.4th 1306 (Jane Doe v. SEC) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jane Doe v. SEC, 28 F.4th 1306 (D.C. Cir. 2022).

Opinion

United States Court of Appeals FOR THE DISTRICT OF COLUMBIA CIRCUIT

Argued January 31, 2022 Decided March 25, 2022

No. 21-1097

JANE DOE, PETITIONER

v.

SECURITIES AND EXCHANGE COMMISSION, RESPONDENT

Consolidated with 21-1098

On Petitions for Review of an Order of the Securities and Exchange Commission

Max Maccoby argued the cause and filed the briefs for petitioner.

Brooke Wagner, Senior Counsel, Securities and Exchange Commission, argued the cause for respondent. With her on the brief were Michael A. Conley, Solicitor, and Stephen G. Yoder, Senior Litigation Counsel.

Before: HENDERSON and TATEL, Circuit Judges, and GINSBURG, Senior Circuit Judge. 2 Opinion for the Court filed Per CURIAM.

Opinion concurring in the judgment filed by Circuit Judge HENDERSON.

The petitioners seek review of a Securities and Exchange Commission (SEC or Commission) order denying their applications for whistleblower awards resulting from a successful SEC enforcement action. They contend that the SEC adopted an unreasonably narrow interpretation of its regulation governing the whistleblower program and that their circumstances satisfy the requirements for award eligibility under a proper reading of the regulation. See 17 C.F.R. § 240.21F-4(c).

We disagree. The SEC properly denied their award applications under its reasonable and longstanding interpretation of the relevant regulation, which sets forth three scenarios allowing for the issuance of a whistleblower award— none of which encompasses the additional scenario proposed by the petitioners. Their additional arguments are either forfeited or meritless. Accordingly, we deny the petitions.

I.

In January 2012, the SEC opened an investigation into alleged violations of the Foreign Corrupt Practices Act of 1977 (FCPA), 15 U.S.C. §§ 78dd-1 et seq., by Novartis AG, a Swiss pharmaceutical company operating in China. The SEC investigation concluded in 2016 when it issued an order settling administrative proceedings against Novartis. It determined that Novartis had violated the books and records and internal accounting controls provisions of the FCPA through its pharmaceutical operations in China. 15 U.S.C. § 78m(b)(2)(A), (B). Specifically, the SEC found that, from 2009 to 2013, employees and agents of two Novartis 3 subsidiaries operating in China provided things of value, such as gifts, travel, entertainment and favors, to Chinese healthcare providers and officials with the goal of increasing Novartis’s pharmaceutical sales in the country. The employees and agents then attempted to conceal the nature of these transactions by using complicit third parties and improperly recording the transactions in the books and records of its subsidiaries.

In the order settling the administrative proceedings with Novartis, the SEC noted that “Novartis instituted an expansive review of its relationships in China with travel and event planning vendors” and subsequently took remedial steps “[i]n connection with the SEC Staff’s investigation and in response to media reports concerning a competitor.” Joint Appendix (J.A.) 5–6. The Commission imposed approximately $25 million in sanctions, ordering Novartis to pay disgorgement of $21,579,217, prejudgment interest of $1,470,887 and a civil penalty of $2,000,000, all of which has been collected in full.

Following the successful enforcement action, the SEC Office of the Whistleblower published a Notice of Covered Action regarding the Novartis proceeding and twelve individuals, including the two petitioners here, filed applications for an award. The SEC’s Claims Review Staff (CRS) reviewed the award claims and determined that only two of the twelve applicants, identified as Claimant 1 and Claimant 2, merited an award because the SEC had opened the investigation based on information provided by those two claimants—not based on information provided by any of the remaining ten. The SEC ordered that Claimant 1 and Claimant 2 receive a joint award. This award has not been challenged. 4 The petition here involves the award claims of Claimant 11 and Claimant 12.1 Each worked for a competitor of Novartis in China; each had informed the SEC of illegal behavior by her employer; and each had subsequently informed American media about that behavior. Media outlets then ran stories about these allegations. Each claimant argued she was entitled to a whistleblower award because, in each claimant’s view, the media reports had caused Novartis to review its practices and ultimately settle with the SEC.

The CRS issued a preliminary denial of their claims because the information they provided did not “[lead] to” the successful enforcement action against Novartis as defined in Exchange Act Rule 21F-4(c). See 17 C.F.R. § 240.21F- 4(c)(1)–(3). The petitioners provided information related to alleged misconduct by two of Novartis’s competitors, not Novartis. Accordingly, the CRS concluded that their information did not cause the opening or reopening of the investigation as required by Rule 21F-4(c)(1). See id. § 240.21F-4(c)(1). They failed to meet the requirements of Rule 21F-4(c)(2) because the information they provided did not relate to conduct already under investigation or examination and did not significantly contribute to the success of the action. See id. § 240.21F-4(c)(2). The CRS reached this conclusion because the reported information involved conduct by different companies and was not used in the Commission’s investigation. Further, the CRS reasoned that the connection between Claimant 11’s and Claimant 12’s submissions of this information to the news media—and its subsequent appearance in various news articles—and the charges in the Novartis action was “tenuous at best,” far from demonstrating a significant 1 The CRS also recommended the denial of award claims by Claimants 3, 4, 5, 6, 7, 8, 9 and 10. These claimants did not contest the preliminary denial and the SEC accordingly did not evaluate their claims in its final order. 5 contribution to the success of the action. Erasing any lingering doubt, the CRS emphasized that “the submissions made by Claimants 11 and 12 to the Commission had no impact whatsoever on the Covered Action.” Finally, the petitioners did not merit an award under Rule 21F-4(c)(3) because, although their submitted information purportedly sparked an internal investigation at Novartis, the findings of which became part of the Covered Action, the petitioners gave the information about Novartis’s competitors to the news media, not to Novartis as required by the Rule. See id. § 240.21F-4(c)(3).

The petitioners then challenged the CRS’s preliminary determination. They argued that the CRS incorrectly concluded that the three fact patterns described in Rule 21F-4(c) were the exclusive routes to satisfy the Rule and that it should have considered “alternative circumstances not specified in” the Rule in analyzing their claims. Notably, they did not contest the CRS’s determination that their circumstances failed to meet the requirements of any of the three fact patterns set forth in Rule 21F-4(c).

Taking up the petitioners’ challenge, the SEC first noted that they “appear to concede that they have not satisfied the three fact patterns set forth in Rule 21F-4(c).” J.A. 293. It then rejected the argument that there are “alternative circumstances not specified in Rule 21F-4(c) in which a claimant can satisfy” the Rule’s “led to” requirement.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Castro
Fifth Circuit, 2025
Wilfredo Felix v. SEC
D.C. Circuit, 2025
Andrei Grenader v. SEC
D.C. Circuit, 2025
Zhou v. McAleenan
District of Columbia, 2025
Battineni v. Mayorkas
District of Columbia, 2024
John Meisel v. Securities and Exchange Commission
97 F.4th 755 (Eleventh Circuit, 2024)
Medica Insurance Company v. Becerra
District of Columbia, 2023
Scott & White Health Plan v. Becerra
District of Columbia, 2023
Ovintiv USA Inc. v. Haaland
District of Columbia, 2023
Pennell v. Nationstar
2022 MT 235 (Montana Supreme Court, 2022)
Eugene Ross v. SEC
D.C. Circuit, 2022

Cite This Page — Counsel Stack

Bluebook (online)
28 F.4th 1306, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jane-doe-v-sec-cadc-2022.